TABLE 2.
Grading of recommendations, assessment, development, and evaluation of primary outcomes and safety of WHD+Azithromycin compared with Azithromycin.
| Outcomes | Detail of outcomes | Studies | Sample size (T/C) | Relative effect (95%CI) | Quality of evidence a (GRADE assessment) |
|---|---|---|---|---|---|
| Primary Outcomes | Response rate | 22 | 1,013/1,013 | RR 1.17 (1.13, 1.21) | Low1,6 |
| Disappearance time of fever | 15 | 724/724 | MD −1.42 (−1.84, −1.00) | Very Low1,3 | |
| Disappearance time of pulmonary rale | 14 | 682/682 | MD −1.97 (−2.31, −1.63) | Very Low1,3 | |
| Disappearance time of wheezing | 9 | 437/438 | MD −1.47 (−1.72, −1.22) | Very Low1,3 | |
| Disappearance time of cough | 16 | 781/781 | MD −2.08 (−2.44, −1.71) | Very Low1,3 | |
| Safety | Adverse rate | 8 | 430/430 | RR 0.42 (0.27, 0.67) | Low1,6 |
RR, odds ratio; MD, mean difference; 95% CI, 95% Credible Interval; GRADE, grading of recommendations, Assessment, Development, and Evaluation.
Interventions: WHD, Wuhu decoctionx.
Estimates for primary outcomes and safety with the Grading of Recommendations, Assessment, Development, and Evaluation Assessment: 1. downgraded because of risk of bias; 2. downgraded one levels because of inconsistency; 3. downgraded two levels because of inconsistency; 4. downgraded because of indirectness; 5. downgraded because of imprecision; 6. downgraded because of publication bias; 7. Upgraded because of Large effects, confounding factors, and quantity-effect relationship.